abhishreshthaa
Abhijeet S
The Babcock & Wilcox Company (B&W) is a U.S.-based company that provides design, engineering, manufacturing, construction and facilities management services to nuclear, renewable, fossil power, industrial and government customers worldwide. B&W's boilers supply more than 300,000 megawatts of installed capacity in over 90 countries around the world.[1]
During World War II, over half of the American US Navy fleet was powered by Babcock & Wilcox boilers.[2] The company has its headquarters in Charlotte, North Carolina with operations in Lynchburg, VA; Barberton, Ohio; West Point, Mississippi; Cambridge, Ontario, Canada; Mount Vernon, Indiana; Oak Ridge, Tennessee; and Euclid, Ohio.
Strengths
* Global presence
* Strong industry standing
* Robust launch portfolio with revenue growth
underscored by the commercialization of
Januvia and Gardasil
* High growth Zetia/Vytorin cardiovascular product franchise
Weaknesses
* Patent expiry for biggest selling product franchise Zocor (mid 2006)
* Weak core portfolio (comprising essentially Zetia/Vytorin) underscored by maturation and migration of key product franchises into expiry portfolio
* Blockbuster growth strategy which closely ties Merck's position in certain therapy markets to just one or two products
Opportunities
* Therapeutic diversification and expansion
into diabetes, oncology and infectious
diseases segments
* Strong potential growth from vaccines
business, driven primarily (but not exclusively) by highly innovative, first-to-market cervical cancer vaccine Gardasil
* Diversification into biologics market via
acquisitions of Abmaxis and GlycoFi
Threats
* Continued exposure to patent expiries and risk of generic competition to key brands across forecast window 2006 to 2012; Fosamax in 2008, Cozaar/Hyzaar in 2009 and Singulair in 2012
* In light of Merck's relatively weak core portfolio and its high generic-exposure expiry portfolio, the company is reliant on considerable sales growth from its launch portfolio, reflecting a higher risk growth strategy versus predominant core-driven growth
During World War II, over half of the American US Navy fleet was powered by Babcock & Wilcox boilers.[2] The company has its headquarters in Charlotte, North Carolina with operations in Lynchburg, VA; Barberton, Ohio; West Point, Mississippi; Cambridge, Ontario, Canada; Mount Vernon, Indiana; Oak Ridge, Tennessee; and Euclid, Ohio.
Strengths
* Global presence
* Strong industry standing
* Robust launch portfolio with revenue growth
underscored by the commercialization of
Januvia and Gardasil
* High growth Zetia/Vytorin cardiovascular product franchise
Weaknesses
* Patent expiry for biggest selling product franchise Zocor (mid 2006)
* Weak core portfolio (comprising essentially Zetia/Vytorin) underscored by maturation and migration of key product franchises into expiry portfolio
* Blockbuster growth strategy which closely ties Merck's position in certain therapy markets to just one or two products
Opportunities
* Therapeutic diversification and expansion
into diabetes, oncology and infectious
diseases segments
* Strong potential growth from vaccines
business, driven primarily (but not exclusively) by highly innovative, first-to-market cervical cancer vaccine Gardasil
* Diversification into biologics market via
acquisitions of Abmaxis and GlycoFi
Threats
* Continued exposure to patent expiries and risk of generic competition to key brands across forecast window 2006 to 2012; Fosamax in 2008, Cozaar/Hyzaar in 2009 and Singulair in 2012
* In light of Merck's relatively weak core portfolio and its high generic-exposure expiry portfolio, the company is reliant on considerable sales growth from its launch portfolio, reflecting a higher risk growth strategy versus predominant core-driven growth